SYDNEY, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology ...
92% of evaluable patients at interim analysis treated with RAD 101 achieved concordance¹ with MRI imaging (the primary endpoint) with significant and selective tumor uptake in suspected or recurrent ...
92% of evaluable patients at interim analysis treated with RAD 101 achieved concordance¹ with MRI imaging (the primary endpoint) with significant and selective tumor uptake in suspected or recurrent ...
Trial shows GRI-0621 improved lung function with signs of fibrosis resolution GRI Bio has announced positive topline results from its phase 2a clinical trial evaluating GRI-0621 in idiopathic ...
Radiopharm Theranostics Limited (NASDAQ: RADX) stock is trading higher on Monday, with a session volume of 21.33 million compared to the average volume of 26.81 thousand, as per data from Benzinga Pro ...
Results from the Precision-T study showed Orca-T significantly improved survival free from chronic GvHD in patients with AML, ALL and MDS compared to a conventional allogeneic hematopoietic stem cell ...
Instil Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel therapies. Its lead products candidate is AXN-2510/IMM2510 that is in Phase 1b/2 clinical trial ...
More than 900 jobs are coming to Montgomery County with a $90.2 million investment as T.RAD auto parts manufacturer comes to Clarksville-Montgomery County Corporate Business Park. The Clarksville ...
GeekWire chronicles the Pacific Northwest startup scene. Sign up for our weekly startup newsletter, and check out the GeekWire funding tracker and VC directory. by Kurt Schlosser on Dec 16, 2025 at ...
HIV hijacks SRRM2 to enlarge nuclear speckles, stabilizing CPSF6 puncta and promoting efficient viral replication.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback